1192813-41-4

Basic information

• Product Name: 2-(difluoromethoxy)-5-nitropyridine
• Synonyms: 2-(difluoromethoxy)-5-nitropyridine
• CAS NO: 1192813-41-4
• Molecular Formula: C6H4F2N2O3
• Molecular Weight: 190.1043664
• Mol File: 1192813-41-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 252.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.464±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -2.80±0.29(Predicted)
• CAS DataBase Reference: 2-(difluoromethoxy)-5-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(difluoromethoxy)-5-nitropyridine(1192813-41-4)
• EPA Substance Registry System: 2-(difluoromethoxy)-5-nitropyridine(1192813-41-4)

Safety Data

• Hazardous Substances Data: 1192813-41-4(Hazardous Substances Data)

Usage

General Description

2-(difluoromethoxy)-5-nitropyridine is a chemical compound that contains a pyridine ring with a difluoromethoxy group at position 2 and a nitro group at position 5. It is an aromatic nitro compound and is used as a building block in the synthesis of various pharmaceuticals and agrochemicals. The difluoromethoxy group provides increased lipophilicity and metabolic stability to the molecule, making it useful in drug design and development. The nitro group can undergo various chemical reactions, making this compound versatile for the creation of different chemical structures. Overall, 2-(difluoromethoxy)-5-nitropyridine has potential applications in the pharmaceutical and agrochemical industries due to its unique chemical properties.

Upstream product

• 5418-51-9 5-nitro-2-hydroxypyridine 
• 1895-39-2 sodium chlorodifluoroacetate 
• 1717-59-5 2,2-difluoro-2-(fluorosulfonyl)acetic acid 

Downstream Products

• 317810-73-4 6-(difluoromethoxy)pyridin-3-amine 

Relevant articles and documents

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Tricyclic Compounds As mPGES-1 Inhibitors

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.